Rare diseases
Investigational molecules
Locations
Recruiting trials first
1 clinical trial in this condition
The NetherlandsIn short
Diagnosing stage I cervical cancer requires careful examination and specialized tests to confirm that cancer is present only in the cervix and has not spread beyond it. Early detection through screening and proper diagnostic procedures helps doctors determine the most appropriate treatment approach for each patient.
Diagnostic tests for stage I cervical cancer are most often needed when abnormal cells are discovered during routine screening tests, such as a Pap smear (also called a Pap test), which examines cells from the cervix under a microscope. If your Pap test shows unusual changes, your doctor will recommend additional tests to determine whether cancer is present and, if so, how far it has developed.
Women who experience certain warning signs should also seek medical evaluation promptly. These symptoms can include unusual vaginal bleeding, such as bleeding after sexual intercourse, bleeding between menstrual periods, or bleeding after menopause. Other signs that warrant a doctor's visit include watery or bloody vaginal discharge that may have a strong odor, or pain during sexual intercourse. Although these symptoms can be caused by conditions other than cancer, they should never be ignored.
It's important to understand that early-stage cervical cancer often causes no symptoms at all, which is why regular screening is so crucial. Many cases of stage I cervical cancer are discovered in women who feel completely well but attend their routine cervical screening appointments. This is exactly why healthcare providers recommend regular Pap tests starting at age 21 and continuing at intervals determined by your age and previous test results.
Women who have not had regular Pap tests in the past are at higher risk for cervical cancer because precancerous changes may have gone undetected. Additionally, those with certain types of human papillomavirus (HPV)—a virus spread through sexual contact that causes most cervical cancers—should be especially vigilant about screening. Even if you've received the HPV vaccine, regular screening remains important because the vaccine doesn't protect against all cancer-causing types of HPV.
When abnormal cells are found during screening, doctors use several specialized tests to determine whether cancer is present and to understand its characteristics. The diagnostic process typically begins with visual examination and proceeds to tissue sampling if needed.
A colposcopy is often the first step after an abnormal Pap test result. During this procedure, your doctor uses a special magnifying instrument called a colposcope to closely examine your cervix. The colposcope doesn't enter your body; instead, it stays outside while providing a magnified view of the cervical tissue. Your doctor may apply special solutions to your cervix that make abnormal areas more visible. This examination helps identify exactly where abnormal cells are located and guides the doctor in deciding where to take tissue samples.
The colposcopy procedure is performed in the doctor's office and is similar to a regular pelvic examination. You'll lie on an examination table with your feet in supports, just as you would for a Pap test. The procedure typically takes 10 to 20 minutes and may cause mild discomfort but is generally not painful. Some women experience light cramping during or after the examination.
If the colposcopy reveals suspicious areas, your doctor will perform a biopsy, which means removing a small sample of tissue for examination under a microscope. This is the only way to definitively diagnose cancer. Several types of biopsy may be used depending on what the colposcopy shows.
A cone biopsy (also called conization) removes a cone-shaped piece of tissue from the cervix. This procedure can serve both as a diagnostic test and as treatment for very early-stage cancers. The tissue sample is larger than what's taken during a simple biopsy, allowing the pathologist to examine the depth of any abnormal cell growth. After removal, the tissue is studied carefully in a laboratory. If cancer cells are found only within the removed tissue and not at its edges—meaning the margins are "clear"—sometimes no further treatment is needed.
Another procedure called LLETZ (large loop excision of the transformation zone) uses a thin wire loop heated by electrical current to remove abnormal tissue from the cervix. Like cone biopsy, this can be both diagnostic and therapeutic for very small, early cancers. These procedures are commonly used for women with abnormal cervical cells detected through screening.
Once cancer is confirmed through biopsy, imaging tests help doctors determine the exact stage of the disease. For stage I cervical cancer, these tests help confirm that the cancer is confined to the cervix and has not spread to nearby tissues or other parts of the body.
Pelvic ultrasound uses sound waves to create images of the organs in your pelvis, including the uterus, cervix, and surrounding structures. This test can be performed in two ways: through your abdomen or through the vagina (called a transvaginal ultrasound). The transvaginal approach often provides clearer images of the cervix and can help assess the size of any tumor present.
CT scans (computed tomography scans) create detailed cross-sectional images of your body using X-rays taken from different angles. A computer combines these images to show your organs and tissues in detail. CT scans help doctors see whether cancer has spread beyond the cervix to lymph nodes or other structures in the pelvis or abdomen.
MRI scans (magnetic resonance imaging) use powerful magnets and radio waves instead of X-rays to create detailed images of soft tissues in your body. MRI is particularly useful for examining the cervix and surrounding pelvic structures because it provides excellent contrast between different types of tissue. This test can show the size of a tumor and whether it has grown into nearby tissues.
In some cases, your doctor may perform a thorough pelvic examination while you're under anesthesia. This allows for a more complete assessment without discomfort. During this examination, the doctor carefully feels the cervix, vagina, bladder, and rectum to check for any signs that cancer has spread to these areas. This examination helps confirm the stage of the cancer.
Doctors use the International Federation of Gynecology and Obstetrics (FIGO) staging system to classify cervical cancer. Stage I is divided into substages based on how deeply the cancer has grown into the cervix and how large it is.
Stage IA cancer is so small it can only be seen with a microscope or colposcope. Stage IA1 means the cancer has grown 3 millimeters or less into the cervical tissue—about the width of a sharp pencil point. Stage IA2 means the cancer has grown more than 3 millimeters but not more than 5 millimeters deep—roughly the size of a new pencil eraser.
Stage IB cancers are larger or have grown deeper than 5 millimeters. These can usually be seen without a microscope, though sometimes they're still detected only through tissue examination. Stage IB1 means the cancer is deeper than 5 millimeters but no more than 2 centimeters in size. Stage IB2 cancers measure between 2 and 4 centimeters, while stage IB3 cancers are larger than 4 centimeters but still confined to the cervix.
If you're considering participating in a clinical trial for cervical cancer treatment, you'll need to undergo specific diagnostic tests to determine whether you meet the trial's eligibility criteria. Clinical trials have strict requirements to ensure participant safety and to collect reliable scientific data.
Most clinical trials for stage I cervical cancer require complete staging information confirmed through the diagnostic methods described earlier. This typically includes documentation of your cancer's exact substage (IA1, IA2, IB1, IB2, or IB3) based on pathology reports from your biopsy. The pathology report must detail how deeply the cancer has invaded the cervical tissue and the maximum diameter of the tumor.
Imaging studies such as MRI or CT scans are often required to confirm that the cancer hasn't spread beyond the cervix. These images provide objective evidence that the cancer remains in stage I, which is essential for trials testing treatments specifically designed for early-stage disease.
Some clinical trials require information about whether cancer has spread to lymph nodes, even though this spread would technically move the cancer beyond stage I. During surgery for cervical cancer, doctors often remove lymph nodes from the pelvis to check them for cancer cells. This procedure is called pelvic lymph node dissection. The lymph nodes are examined under a microscope to look for any sign of cancer spread.
A newer approach called sentinel lymph node biopsy may be used in some trials. This technique identifies the first lymph node (or nodes) that cancer cells would most likely spread to from the original tumor—the "sentinel" node. A special dye or radioactive tracer is injected near the tumor, and the doctor tracks where it flows to find this sentinel node. If the sentinel node is free of cancer, the other lymph nodes are typically also cancer-free, potentially avoiding the need to remove many lymph nodes.
Clinical trials may require special testing of your tumor tissue beyond standard diagnosis. For example, researchers might need to know the specific type of cervical cancer you have—whether it's squamous cell carcinoma (cancer that starts in the flat, thin cells lining the outer part of the cervix) or adenocarcinoma (cancer that starts in the gland cells lining the inside of the cervix). About 80 to 90 percent of cervical cancers are squamous cell carcinomas, while 10 to 20 percent are adenocarcinomas.
Some trials focus on tumors with specific characteristics. For instance, a trial might require that your tumor be smaller than 2 centimeters, have less than 10 millimeters of invasion into the cervical tissue, and show no lymphovascular space invasion (LVSI)—which means cancer cells haven't entered blood vessels or lymph vessels in the tissue. These "low-risk" criteria help researchers study whether less extensive surgery might be safe for carefully selected patients.
Testing for HPV is standard in cervical cancer screening, and some clinical trials may require specific information about which type of HPV is present in your tumor. There are more than 100 types of HPV, and about a dozen are known to cause cancer. Identifying the specific high-risk HPV type may be important for certain research studies, particularly those investigating how different HPV types respond to treatment.
Before enrolling in a clinical trial, you'll typically need blood tests to check your general health. These tests examine your blood cell counts to ensure your bone marrow is producing enough red blood cells, white blood cells, and platelets. They also check your kidney and liver function to make sure these organs are working properly. Clinical trials have specific thresholds for these values to ensure participants are healthy enough to receive the experimental treatment being studied.
If preserving your ability to have children in the future is important to you, mention this during diagnostic discussions. Some clinical trials specifically study fertility-preserving treatments for early-stage cervical cancer. These trials may have additional requirements, such as confirming through imaging that the tumor is small enough to allow removal of just the cervix rather than the entire uterus. Your age and whether you've completed your family may also factor into trial eligibility.
The outlook for patients with stage I cervical cancer is generally favorable, especially when the cancer is detected early and treated promptly. Stage I means the cancer is confined to the cervix and hasn't spread to nearby tissues or other organs, which significantly improves the chances of successful treatment. The specific substage matters: patients with stage IA disease (visible only under a microscope) typically have an excellent prognosis, while those with larger stage IB tumors may face slightly more complex treatment but still have good outcomes overall. Several factors influence prognosis beyond just the stage. These include the size of the tumor, how deeply it has invaded the cervical tissue, whether cancer cells have entered blood vessels or lymph vessels (lymphovascular space invasion), and the type of cervical cancer (squamous cell carcinoma or adenocarcinoma). Patients whose tumors show no lymphovascular space invasion and whose lymph nodes are free of cancer generally have the best outcomes. Age and overall health also play a role in recovery and long-term prognosis.
More than 90 percent of early-stage cervical cancers are treated successfully with surgical procedures, and many patients do not require any additional treatment beyond surgery. This means that the vast majority of women diagnosed with stage I cervical cancer can expect to be cured of their disease. The high success rate reflects both the effectiveness of modern surgical techniques and the benefit of detecting cancer before it has spread beyond the cervix. Stage I cervical cancer is considered highly treatable when found early, which underscores the critical importance of regular cervical screening with Pap tests. Women who attend routine screenings are more likely to have any cancer detected at this early, very treatable stage.
This guide is here to help you understand the condition. It does not replace a conversation with your doctor, who knows your situation best.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
